Pre-Approval Expanded Access Study for TAR-200 Treating Physician Use
NCT06877676
·
clinicaltrials.gov ↗
APPROVED_FOR_MARKETING
Status
INDUSTRY
Sponsor class
Conditions
Non-Muscle Invasive Bladder Neoplasms
Interventions
DRUG:
TAR-200
Sponsor
Janssen Research & Development, LLC